BacterioScan
Innovative diagnostic solutions for rapid, precise UTI detection, reducing healthcare strain with patented technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | N/A | Bankruptcy | |
| Total Funding | 000k | ||
Related Content
BacterioScan, Inc. specializes in transforming the diagnosis of urinary tract infections (UTIs) with its award-winning BacterioScan 216Dx device. This innovative technology detects and measures bacterial growth in clinical urine specimens within just 3 hours, and their latest patented solution can do so in as little as 45 minutes. The company primarily serves healthcare providers, including hospitals and laboratories, aiming to improve patient care and reduce unnecessary antibiotic prescriptions. Operating in the medical diagnostics market, BacterioScan's business model revolves around selling their diagnostic devices and related services. Revenue is generated through direct sales, service contracts, and potentially licensing their patented technology. The company’s focus on rapid, accurate, and cost-effective UTI detection positions it as a key player in enhancing lab and hospital economics, improving antibiotic stewardship, and expediting patient discharge.
Keywords: UTI detection, diagnostic device, bacterial growth, healthcare, hospitals, laboratories, rapid diagnosis, patented technology, antibiotic stewardship, patient care.